These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 14508085)

  • 1. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
    Senderowicz AM
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule cyclin-dependent kinase modulators.
    Senderowicz AM
    Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
    Senderowicz AM
    Leukemia; 2001 Jan; 15(1):1-9. PubMed ID: 11243375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell cycle modulators for the treatment of lung malignancies.
    Senderowicz AM
    Clin Lung Cancer; 2003 Nov; 5(3):158-68. PubMed ID: 14667271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule modulators of cyclin-dependent kinases for cancer therapy.
    Senderowicz AM
    Oncogene; 2000 Dec; 19(56):6600-6. PubMed ID: 11426645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S; Roberts JD
    Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
    Senderowicz AM
    Prog Drug Res; 2005; 63():183-206. PubMed ID: 16265881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinases as targets for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and clinical development of cyclin-dependent kinase modulators.
    Senderowicz AM; Sausville EA
    J Natl Cancer Inst; 2000 Mar; 92(5):376-87. PubMed ID: 10699068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
    Senderowicz AM
    Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early development of cyclin dependent kinase modulators.
    Roy KK; Sausville EA
    Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
    Whittaker SR; Walton MI; Garrett MD; Workman P
    Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
    Akiyama T; Sugiyama K; Shimizu M; Tamaoki T; Akinaga S
    Jpn J Cancer Res; 1999 Dec; 90(12):1364-72. PubMed ID: 10665655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
    Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
    Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.
    Senderowicz AM
    Oncologist; 2002; 7 Suppl 3():12-9. PubMed ID: 12165651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
    Lara PN; Mack PC; Synold T; Frankel P; Longmate J; Gumerlock PH; Doroshow JH; Gandara DR
    Clin Cancer Res; 2005 Jun; 11(12):4444-50. PubMed ID: 15958629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
    Senderowicz AM
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1229-53. PubMed ID: 12512390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
    Zhai S; Senderowicz AM; Sausville EA; Figg WD
    Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.